Lisa Bright

Lisa Bright is an accomplished professional with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as a Non Executive Director at Ascendis Pharma A/S and Immedica Pharma AB, Lisa is also involved as a Strategic Advisor at DRI Capital and an Advisor on the Commercial Launch Advisory Board for Autolus Therapeutics. Previous roles include Non Executive Director at Dechra Pharmaceuticals PLC and Chair of the Board at Resolution Therapeutics, where Lisa also chaired the Nomination Committee. Formerly, Lisa held key positions at Gilead Sciences, including Chief Commercial and Corporate Affairs Officer, and President International at Intercept Pharmaceuticals. Lisa earned a BSc Hons in Pharmacology from UCL and has a strong background in leading commercial strategies and governance in the life sciences industry.